Newswire

A PBM Oligopoly: Three Companies Control 80% Of US Prescriptions – How Can We Fix It?

States Keep Legal Pressure on PBMs Ahead of Potential FTC Suit

Lawmakers introduce bipartisan bill aiming to crack down on drug middlemen as scrutiny ramps up

Pharmacy middlemen claim to keep prescription prices low. In fact, they’ve cost consumers billions

Insurers, employers see payoffs switching to smaller PBMs

Medicare Advantage and Consolidation’s New Frontier — The Danger of UnitedHealthcare for All

Spanberger Joins More Than 20 Colleagues in a Bipartisan, Bicameral Effort Urging the Defense Health Agency to Increase Oversight of Its Exclusive Contract with Express Scripts

Independent local pharmacies at risk as reimbursement environment prompting closures

Health-Care Collusion Task Force Sets Stage for DOJ Enforcement

Price-gouging middlemen are why Arizonans can’t afford their prescriptions

Independent pharmacists start ads asking Congress for relief from PBMs, ask Supreme Court to hear a case

States urge Supreme Court to review PBM case

PBM executives invited to testify before House panel

Critics of Pharmacy Benefit Managers to Protest at Express Scripts

When Did Progressives Learn to Love Health Insurers?

Mark Cuban has a simple question for CVS’s drug middleman: Why don’t you publish your prices?

Congress Has A Big Chance To Investigate A Financial Threat To Patients

Not so fast, PBMs: You aren’t fooling consumers

The federal government will soon announce its payment rates and policy changes for the Medicare Advantage program. Here's how you can influence their decision.

Amid increased federal scrutiny, PBMs pivot strategy to further squeeze independent pharmacies